arrow
B

Brian Gastman

Cleveland Clinic Foundation
H指数:48
被引数:8,073

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles

推进实体瘤细胞疗法:克服生物学、操作和监管障碍的途径

2026-02-260
PRE
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors

利菲鲁赛(Lifileucel)肿瘤浸润淋巴细胞细胞疗法在免疫检查点抑制剂治疗后疾病进展的不可切除或转移性黏膜黑色素瘤患者中的应用

2025-07-220
OAAI
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial

Pembrolizumab在II期黑色素瘤中的辅助治疗: 随机,双盲,III期KEYNOTE-716试验中原发性肿瘤位置的结果

2025-02-010
PRE
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
2024-02-231
OA
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)
2024-01-040
OAAI
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果 (10.1038 10月16日/s41591-023-02583-2,2023)

2023-11-030
OAAI
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果

2023-10-1653
OAAI
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (2022年12月1至3日-意大利那不勒斯)

2023-07-282
OAAI
A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
2023-04-144
PRE